Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 344

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 8
Chunk 344
---
        )
         
        $
        (265,964
        )
         
        $
        (333,928
        )

        Denominator:

        Weighted-average common shares outstanding, basic   and diluted

        119,849

        63,306

        63,032

        Net loss per share attributable to common stockholders,   basic and diluted
         
        $
        (6.23
        )
         
        $
        (4.20
        )
         
        $
        (5.30
        )
       
       The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 9, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of the warrant, potentially dilutive shares are based on the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024. 

        As of December 31,

        2024

        2023

        2022

        Stock options outstanding

        —

        210,000

        210,000

        Convertible preferred stock

        —

        63,525,953

        62,692,927

        AstraZeneca warrant

        —

        1,744,991

        1,744,991

        Mpirik holdback liability

        —

        8,724

        —

        SEngine holdback liability

        —

        41,436

        —

        Unvested RSUs

        6,873,974

        —

        —

        Allen & Company warrant

        —

        150,000

        —

        Total potentially dilutive shares

        6,873,974

        65,681,104

        64,647,918

       As disclosed in Note 11, the RSUs issued prior to the IPO include a liquidity event performance condition prior to vesting. As such, as of December 31, 2023 and 2022, these are treated as contingently issuable shares and are excluded from potentially dilutive shares as the liquidity event performance condition was not yet satisfied. As the liquidity event performance condition was satisfied upon completion of the IPO, as of December 31, 2024, these shares are